DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Ulimorelin is an investigational drug.
There have been 7 clinical trials for Ulimorelin. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2011.
The most common disease conditions in clinical trials are Gastrointestinal Diseases, Digestive System Diseases, and Liver Diseases. The leading clinical trial sponsors are Norgine, Tranzyme, Inc., and Lyric Pharmaceuticals.
There are nine US patents protecting this investigational drug and forty-seven international patents.
Recent Clinical Trials for Ulimorelin
|Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial||Lyric Pharmaceuticals||Phase 2|
|A Study to Assess Ulimorelin in Healthy Subjects||Lyric Pharmaceuticals||Phase 1|
|A Study to Evaluate the Safety of TZP-101 (IV Ulimorelin) Administered Post-Operatively in Patients Who Have Undergone Partial Bowel Resection||Norgine||Phase 3|
Top disease conditions for Ulimorelin
Top clinical trial sponsors for Ulimorelin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Ulimorelin||Start Trial||Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists||Tranzyme Pharma, Inc. (CA)||Start Trial|
|Ulimorelin||Start Trial||Macrocyclic modulators of the ghrelin receptor||Tranzyme Pharma, Inc. (Quebec, CA)||Start Trial|
|Ulimorelin||Start Trial||Methods of using macrocyclic modulators of the ghrelin receptor||Tranzyme Pharma Inc. (Quebec, CA)||Start Trial|
|Ulimorelin||Start Trial||Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders||Tranzyme Pharma Inc. (CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|